Oculis joins MS campaign with vision focus
- Oculis (NASDAQ:OCS) joined the National Multiple Sclerosis Society’s Campaign to End MS as an industry partner focused on vision.
- The company is advancing the PIONEER program, which includes two trials for Privosegtor in optic neuritis.
- Oculis expects to submit an investigational new drug application for acute MS relapses in Q4 2026 following FDA feedback.
Oculis (NASDAQ:OCS) joined the National Multiple Sclerosis Society’s Campaign to End MS as an industry partner focused on advancing research and care related to vision problems in multiple sclerosis.
The five-year campaign aims to accelerate MS research and improve access to care, while Oculis is developing Privosegtor through its PIONEER program for optic neuritis.
The PIONEER program includes two clinical trials designed to support registration of Privosegtor for optic neuritis, while Oculis reported that it received positive FDA feedback ahead of submitting an investigational new drug application.
Oculis expects to submit an investigational new drug application for treating acute MS relapses in the fourth quarter of 2026, expanding the potential development focus of Privosegtor.
The company also plans to hold an R&D Day in the fourth quarter of 2026 to provide updates on its pipeline and development programs.
